Bortezomib Triplet Improves Outcomes in Newly Diagnosed Multiple Myeloma
Adding bortezomib to lenalidomide and dexamethasone improved progression-free and overall survival in patients with newly diagnosed multiple myeloma who were not planned for immediate stem-cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - January 18, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news
Frontline Triplet With Bortezomib: New Standard in Myeloma? Frontline Triplet With Bortezomib: New Standard in Myeloma?
Bortezomib added to lenalidomide plus dexamethasone significantly increased both progression-free and overall survival in multiple myeloma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Lenalidomide Maintenance Improves Survival in Poor Prognosis DLBCL
Lenalidomide maintenance significantly improves survival in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). (Source: CancerNetwork)
Source: CancerNetwork - December 14, 2016 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Conferences/ASH 2016 Leukemia & Lymphoma News Source Type: news
Myeloma XI ’s Phase III trial result shows increase in myeloma patient remission
Myeloma XI has reported that the Phase III trial conducted in myeloma has indicated a 95% increase in progression-free survival (PFS) in myeloma patients receiving lenalidomide maintenance treatment. (Source: Drug Development Technology)
Source: Drug Development Technology - December 8, 2016 Category: Pharmaceuticals Source Type: news
Maintenance Lenalidomide Prolongs PFS in High-Risk CLL Maintenance Lenalidomide Prolongs PFS in High-Risk CLL
High-risk patients with CLL who receive lenalidomide as maintenance therapy following response to induction therapy have longer PFS compared with placebo.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Moffitt Cancer Center study shows improved response rates in myelodysplastic syndromes patients treated with lenalidomide and epoetin alpha
(H. Lee Moffitt Cancer Center& Research Institute) Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia. Many patients with lower-risk MDS benefit from treatment with recombinant-erythropoietin (rHuEPO), which stimulates blood cell production. However, patients who become refractory to rHuEPO have few effective treatment options. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2016 Category: Cancer & Oncology Source Type: news
FDA Approves Daratumumab Combinations for Previously Treated Myeloma
The FDA has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 2, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
HORSHAM, Pa., Nov. 21, 2016 -- (Healthcare Sales & Marketing Network) -- Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone, or bort... Biopharmaceuticals, Oncology, FDA Janssen Biotech, DARZALEX, daratumumab, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 22, 2016 Category: Pharmaceuticals Source Type: news
Darzalex (daratumumab) Approved by FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
HORSHAM, PA, Nov. 21, 2016 – Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2016 Category: Drugs & Pharmacology Source Type: news
Daratumumab Combo Significantly Improved PFS for Relapsed Myeloma
Adding daratumumab to lenalidomide and dexamethasone significantly improved progression-free survival in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - October 5, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news
Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selexinor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news
Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selinexor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news
EMA grants positive opinion for Takeda ’s NINLARO to treat multiple myeloma in adult patients
European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the conditional approval of Takeda Pharmaceutical's NINLAROTM (ixazomib) capsules in combination with lenalidomide and d… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 18, 2016 Category: Pharmaceuticals Source Type: news
Lenalidomide in Adult ATL Shows Further Promise
Use of lenalidomide monotherapy in patients with adult T-cell leukemia/lymphoma resulted in clinically meaningful antitumor activity, with 42% of phase II trial participants having objective responses. (Source: CancerNetwork)
Source: CancerNetwork - September 13, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news
Adding Carfilzomib Improved Health-Related QoL for Multiple Myeloma Patients
The addition of carfilzomib to lenalidomide and dexamethasone improved health-related quality of life compared with treatment with lenalidomide/dexamethasone alone among patients with relapsed multiple myeloma enrolled in the ASPIRE trial. (Source: CancerNetwork)
Source: CancerNetwork - September 7, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news
